Palatin Technologies (PTN) Interest Coverage Ratio (2010 - 2026)
Palatin Technologies' (PTN) quarterly Interest Coverage Ratio came in at 1246.84 in Q1 2026, up 53.5% on a YoY basis from 812.27 in Q1 2025, and up 91.53% quarter-over-quarter from 14715.96 in Q4 2025.
Powered by 
Analysis
Palatin Technologies (PTN) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Interest Coverage Ratio for 16 consecutive years, with 1246.84 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 53.5% year-over-year to 1246.84; the trailing twelve-month figure through Mar 2026 stood at 898.59 (up 55.94% YoY), and the FY2025 full-year result was 1162.06, down 3499.97% from the prior year.
- Interest Coverage Ratio rose to 1246.84 in Q1 2026 per PTN's latest filing, from 14715.96 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2328.2 in Q3 2025 and bottomed at 14715.96 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 2214.83 across 5 years, with a median of 911.55 in 2022.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio sank 40890.64% in 2024, then soared 278.11% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 5.01 in 2022, then soared by 133.62% to 1.68 in 2023, then sank by 40890.64% to 686.65 in 2024, then tumbled by 2043.16% to 14715.96 in 2025, then soared by 91.53% to 1246.84 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1246.84, 14715.96, and 2328.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -1,246.84 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,246.84 |
| Dec 31, 2025 | -14,715.96 |
| Sep 30, 2025 | 2,328.20 |
| Jun 30, 2025 | -651.21 |
| Mar 31, 2025 | -2,681.44 |
| Dec 31, 2024 | -686.65 |
| Sep 30, 2024 | -1,307.19 |
| Mar 31, 2024 | -7,351.11 |
| Dec 31, 2023 | 1.68 |
| Sep 30, 2023 | -561.38 |
| Mar 31, 2023 | -2,126.17 |
| Dec 31, 2022 | -5.01 |
| Sep 30, 2022 | -911.55 |
| Jun 30, 2022 | -717.51 |
| Mar 31, 2022 | -2,590.40 |
| Dec 31, 2021 | -3,047.67 |
| Sep 30, 2021 | -1,281.43 |
| Jun 30, 2021 | -973.21 |
| Dec 31, 2020 | -4,943.72 |
| Sep 30, 2020 | -526.83 |